Lynn Amarante, MD
Dermatology · Williamsville, NYNPI 1568456564
Payments from drug & device makers
Across 146 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$730
- Novartis$433
- Sun Pharmaceutical Industries Inc.$279
- UCB, Inc.$271
- Regeneron Healthcare Solutions, Inc.$257
- Lilly USA, LLC$185
- plus $745 from 15 others
What the payments were for
- Food & beverage$2,901100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $730 |
| Novartis | 22 | $433 |
| Sun Pharmaceutical Industries Inc. | 14 | $279 |
| UCB, Inc. | 13 | $271 |
| Regeneron Healthcare Solutions, Inc. | 10 | $257 |
| Lilly USA, LLC | 10 | $185 |
| Sanofi | 7 | $166 |
| Galderma Laboratories, L.p. | 6 | $90 |
| Pfizer | 4 | $86 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $58 |
| Incyte Corporation | 2 | $48 |
| Johnson & Johnson | 2 | $41 |
| Nabriva Therapeutics, PLC | 2 | $39 |
| Amgen | 3 | $39 |
| Boehringer Ingelheim | 2 | $38 |
| Dermavant Sciences, Inc. | 2 | $30 |
| Dermira, Inc. | 2 | $29 |
| VYNE Pharmaceuticals Inc. | 1 | $25 |
| Almirall LLC | 1 | $23 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$2,901 in reported general payments places this provider in the 50th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 280 | $13,253 |
| Metronidazole | 88 | $5,429 |
| GriseofulvinGriseofulvin, Microsize | 15 | $5,206 |
| Halobetasol Propionate | 63 | $4,264 |
| Pimecrolimus | 11 | $4,208 |
| Betamethasone Dipropionate | 45 | $4,061 |
| Ketoconazole | 130 | $3,583 |
| Triamcinolone Acetonide | 165 | $3,279 |
| CiclopiroxCiclopirox Olamine | 76 | $2,031 |
| Imiquimod | 34 | $1,454 |
| Mometasone Furoate | 41 | $1,351 |
| Azelaic Acid | 17 | $1,282 |
| Ciclopirox | 27 | $1,239 |
| Fluorouracil | 18 | $1,238 |
| Doxycycline Hyclate | 61 | $932 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Williamsville
- Michael NazarethWilliamsville$849K
- Animesh SinhaWilliamsville$414K
- Robert KalbWilliamsville$383K
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- John TuRochester$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.